drugset / Trial / NCT00329173

PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.

NCT00329173

Phase 3 Completed 1000 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment

Timeline

Start
2003-11
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg
Subject Rosuvastatin Small molecule 10 mg

Indications